Cue Biopharma, Inc. logo

Cue Biopharma, Inc.

Immune Responses, On Cue.
Developing novel biologics that could overcome the challenges facing prevailing immunotherapeutics. Cue Biopharma (formerly known as Imagen Biopharma Inc.) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease.

The technology underlying Cues approach was developed from research at the Albert Einstein College of Medicine in New York and was supported by National Institutes of Health grant funding.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”CUE” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.cuebiopharma.com
Founded2014
Disease Focus
Development Stage
STOCK CODENASDAQ: CUE
Address
675 W Kendall Street, MA 02142
Cambridge
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cuebiopharma” connections=”true” suffix=””]

Cue biologics are being designed to achieve a high level of specificity through the fusion of engineered T cell costimulatory signaling molecules (ligands) with a T cell receptor targeting complex (peptide-MHC) on a traditional antibody scaffold. The peptide interacts with disease-relevant T cells and the biologic delivers one of Cues engineered signaling ligands, thereby enabling exclusive modulation of the T cell population of interest

In Dec 2017, Cue Biopharma raised $66.2 Mn through IPO. In earlier 2017, it raised $16.4 Mn in follow-on financing in new capital, led by MDB Capital Group. This investment follows $10 Mn in seed funding the company raised after it was founded in 2015.